International PCT Patent Filed for Ketim’s Postpartum Depression Biomarker Technology
Brisbane, Australia – February 4, 2026 – Ketim Technologies has officially filed an international Patent Cooperation Treaty (PCT) application, marking a major milestone in protecting its proprietary biomarker technology for postpartum depression risk prediction.
The PCT filing protects Ketim’s discovered protein biomarker signatures identified through research conducted within the Queensland Family Cohort and subsequent validation work. The application secures international priority as the company advances development of its in vitro diagnostic (IVD) platform for postpartum depression.
The milestone follows two years of scientific discovery, translational development, and structured intellectual property strategy, including provisional filings and trademark protections.
“Securing international patent protection is a foundational step in building a defensible precision psychiatry platform,” said Dr. Clarissa Yates, Founder and CEO. “It reflects the depth of research behind our biomarker discoveries and strengthens our pathway toward clinical and global market deployment.”
The filing complements Ketim’s ongoing validation studies in collaboration with AGRF Ltd and Olink Proteomics and reinforces support from its advisors, board members, and early backers including AngelLoop, Advance Queensland, and the Brisbane Economic Development Agency.
The PCT application marks a critical step in safeguarding the company’s intellectual property as it progresses toward regulatory milestones and international expansion.
For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au
